StockData

Harvard Bioscience vs Senseonics

HBIO and SENS side by side, both in laboratory apparatus and analytical, optical, measuring, and controlling instruments. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How HBIO and SENS compare

Senseonics is the larger company, worth 14 times as much as Harvard Bioscience ($576M against $40.6M).

Senseonics grew revenue faster over the last twelve months (90.6% versus −1.1% for Harvard Bioscience).

Harvard Bioscience keeps more of each dollar of sales as profit, with a net margin of −11.9% compared with −225% at Senseonics.

Senseonics scores higher on the StockData Score (6 against 3 for Harvard Bioscience), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricHBIOSENS
Size and price
Market cap$40.6M$576M
Share price$8.91$10.90
Change, 1 year53.0%76.4%
Change, 5 years−87.1%−83.1%
Beta (5Y)2.012.36
Employees339130
StockData Score
Total score36 (better)
Valuation score00
Growth score14 (better)
Performance score11
Health score11
Dividend score00
Valuation
P/S0.5× (better)11.9×
P/B5.5× (better)6.4×
FCF yield−2.8% (better)−16.8%
Fair value$6.45$8.08
Margin of safety−38.1%−34.8% (better)
Growth
Revenue growth (TTM)−1.1%90.6% (better)
Revenue growth, 5Y average−3.3%48.1% (better)
Profitability
Gross margin58.2% (better)54.9%
Operating margin−0.28% (better)−223%
Net margin−11.9% (better)−225%
FCF margin−1.3% (better)−199%
Return on equity−89.9% (better)−118%
Return on invested capital−0.84%–
Financial health
Debt / equity4.95–
Interest coverage–−21.0×
Current ratio1.876.74 (better)
Altman Z-score−2.22 (better)−5.39
Piotroski F-score36 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions36.9%39.4%
Held by insiders–5.7%
Insider net buying, 12 months$202K$451K (better)
Short interest, % of float–9.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.